News: Perspective’s Bamzireotide Navoxetan (VMT-α-NET) Demonstrates Encouraging Safety, Durable Disease Control, and Robust Tumor Response Across Multiple Dose Cohorts in Phase 1/2a Trial in Advanced SSTR2-Expressing NETs Updated interim data presented at #ESMO26 today show that in the ongoing Phase 1/2a study in patients with SSTR2-positive NETs who had not received prior #radiopharmaceutical therapy, disease control rate (DCR) was 89% in Cohort 2 (5.0 mCi, n=46) and 95% in Cohort 3 (6.0 mCi, n=20). Progression-free survival (PFS) was 72% at 18 months across all cohorts. Objective response rates (ORRs), including unconfirmed responses, were 33% and 50% in Cohorts 2 and Cohort 3, respectively. Higher responses were observed in Cohort 3 relative to Cohort 2 at early assessments. No dose-limiting toxicities (DLTs), Grade 4 or 5 treatment-emergent adverse events (TEAEs), or adverse event-related treatment discontinuations were reported. We're aiming to complete Phase 3 site start-up preparations around year-end 2026, positioning us to rapidly activate clinical sites following an End-of-Phase 2 meeting with the FDA, with Phase 3 initiation expected in 2027. Perspective will hold a conference call to discuss the results today at 2pm EDT / 8pm CEST. Join the webcast: viavid.webcasts.com/starther… Read more in our press release: tinyurl.com/msk9yf5s #CATX #TargetedOncology

Targeted delivery has already transformed #oncology through approaches such as ADCs and T-cell engagers. #Radiopharmaceuticals extend that principle by pairing tumor targeting with a highly potent radiation payload. As Chief Science Officer Paul Lyne notes, targeted alpha therapies are especially compelling because alpha particles deliver intense energy over a very short distance, designed to maximize tumor damage while limiting exposure to surrounding healthy tissue. That combination of precision and potency is a key reason targeted alpha therapy is one of oncology’s most promising modalities. #CATX #TargetedOncology

An active Fall season continues for the Perspective team. We're on the ground early next week at #EANM2026 in Vienna. Connect with us to discuss our lead-based #theranostic approach and how we’re applying it across SSTR2, MC1R, and FAP-α programs. #Radiopharmaceuticals #TargetedOncology

Broader RPT adoption will take more than new therapies. Perspective was very pleased to join Lilly as an industry co-lead for American Society for Radiation Oncology (ASTRO)'s sixth #Radiopharmaceutical Therapy Roundtable in Boston last month. The discussion focused on what needs to be in place for broader adoption: multidisciplinary care, trial-ready sites, trained teams, appropriate infrastructure, and workable reimbursement models. Thanks to ASTRO and colleagues across the industry, academia, and clinical practice for a productive discussion on what comes next. #ASTRO26 #TargetedOncology

News: Perspective Therapeutics Granted Fast Track Designation for [²¹²Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous Tumors PSV359 is an investigational FAP-targeted alpha-particle therapy being evaluated in an ongoing Phase 1/2a study in patients with advanced FAP-positive solid tumors. Early human imaging data for PSV359 support strong tumor uptake and fast renal clearance. Read more in our press release: tinyurl.com/yck3ycbz #CATX #TargetedOncology #FDA #FastTrack

News: Perspective Therapeutics Announces Acceptance of [²¹²Pb]VMT-α-NET Data for Presentation at the NANETS 2026 Multidisciplinary NET Medical Symposium The November 5th oral presentation will provide a cohort-level look at safety and efficacy in patients with advanced SSTR2-positive neuroendocrine tumors. VMT-α-NET (bamzireotide navoxetan) is currently in an ongoing Phase 1/2a study, with additional clinical updates expected through 2026 as we advance the program toward a potential registration study. tinyurl.com/ympvxv5d #CATX #TargetedOncology #NANETS2026

News: Perspective Therapeutics Announces Acceptance of [²¹²Pb]VMT01 Data for Presentation at SITC 2026 VMT01 is being studied in previously treated unresectable or metastatic #melanoma, both as monotherapy and in combination with nivolumab. Early data from the 3.0 mCi monotherapy cohort showed objective responses and disease stabilization in heavily pretreated patients. No dose-limiting toxicities have been observed at doses studied. Data from the ongoing Phase 1/2a study will be presented November 6 at #SITC2026. tinyurl.com/53hp59xf #CATX #TargetedOncology #Immunotherapy

Perspective VP, Pipeline Discovery Mengshi Li will present at Discovery on Target 2026 as part of the “Next Wave of Innovation in Radioligand Therapies” session. Mengshi will discuss lead-212, including its scalable and cost-effective supply chain; clinical results from Perspective’s ongoing trials; and next-generation peptides directed at novel oncology targets. Date: September 29, 9:35 - 10:05 AM ET Presentation Name: Advances in ²¹²Pb Alpha-Particle Radiopharmaceutical Therapeutics Learn more: discoveryontarget.com/radiol… #CATX #Radiopharmaceuticals #TargetedOncology

This Sunday in Boston, we'll join Lilly in leading the #ASTRO26 Radiopharmaceutical Therapy Roundtable in Boston, helping to shape the discussion on what comes next for #RPT. Topics will include clinical trial readiness, multidisciplinary care, infrastructure, reimbursement, and broader adoption. Amos Hedt, Chief Business Strategy Officer, and Shilpen Patel, SVP, Clinical Development will be onsite representing Perspective. Looking forward to a thoughtful discussion with ASTRO and colleagues from across the field.

Last week, CEO Thijs Spoor joined the Morgan Stanley Global Healthcare Conference for a broad discussion on Perspective's development priorities and outlook. Topics ranged from upcoming clinical milestones to how Perspective is thinking about capital allocation as we advance multiple programs. Listen to the replay: event.webcasts.com/viewer/ev…

Therapeutic window, or the balance between anti-tumor activity and safety and tolerability, is central to how we think about developing targeted alpha therapies. At the Cantor Global Healthcare Conference, Perspective CEO Thijs Spoor discussed how the VMT-α-NET profile observed to date informs our understanding of the therapeutic window, and the importance of longer-term follow-up. #CATX #Radiopharmaceuticals #TargetedOncology

Perspective CEO Thijs Spoor, Chief Science Officer Paul Lyne, and Chief Business Strategy Officer Amos Hedt are on the ground at the Oppenheimer & Co. Inc. Targeted Radiopharmaceutical Therapies in Oncology Summit today. Thijs will join a panel on the evolving isotope landscape and what it means for radiopharmaceutical development and manufacturing, while Paul will discuss how to put emerging TRT clinical data in context. Connect with us to discuss our lead-212 targeted alpha therapies, three advancing clinical-stage oncology programs, and the manufacturing network we're building to support reliable supply and direct-to-hospital delivery. #CATX #Radiopharmaceuticals #TargetedOncology

CEO Thijs Spoor joins the Morgan Stanley Global Healthcare Conference today for a fireside chat at 11:30 AM ET. The discussion will include the path toward Phase 3 for VMT-α-NET, upcoming clinical milestones across the pipeline, and manufacturing readiness to support later-stage development. Watch the webcast here: tinyurl.com/ycye625t

News: Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [²¹²Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid Tumors Read the press release for more: tinyurl.com/bdeppsyr

Press Release | Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the 38th EORTC-NCI-AACR Symposium 2026. The poster presentation will feature cohort-level safety and efficacy results from Cohorts 1–3 in patients with advanced SSTR2-expressing neuroendocrine tumors (NETs). Read more: tinyurl.com/58h22puf #CATX #TargetedOncology #ENAsymp26

At the 2026 Cantor Global Healthcare Conference, CEO Thijs Spoor discussed Perspective's development plans, regulatory path, and manufacturing and supply chain progress. The conversation reflects how we’re approaching the next phase of the Company: advancing our clinical programs while building the infrastructure needed to reliably deliver patient doses at scale. #CATX #TargetedOncology #Manufacturing

Perspective is very pleased to welcome Shilpen Patel as Senior Vice President, Clinical Development. Shilpen brings more than 20 years of oncology clinical development experience spanning Phase 1–4 studies. Most recently, he served as Global Development Lead and Asset Lead at AbbVie, following earlier roles at Gilead, Genentech/Roche, and GRAIL. A board-certified physician, he is also an Associate Professor at the University of Washington/Fred Hutchinson Cancer Center. As we advance our lead program toward Phase 3 development, Shilpen’s deep oncology and clinical development expertise will be especially valuable. Welcome to the team, Shilpen!

We followed patients treated with investigational targeted alpha radiopharmaceutical therapy VMT-α-NET over 22 months of study, tracking how tumors responded. The data show responses generally deepened over time, with more patients reaching objective response the longer they were followed. Most recent data presented at ASCO 2026, with data cutoff date of April 17, 2026. For more, see: tinyurl.com/mrxxpxub and tinyurl.com/4zujhp6r #CATX #Radiopharmaceuticals #TargetedOncology

Lead-212 targeted alpha therapy may do more than kill tumor cells. It may also promote immune activation. In preclinical melanoma models in mice, Perspective’s investigational therapy VMT01 triggered a tumor-specific immune response and showed cooperative anti-tumor effects with two checkpoint inhibitors. Lead-212 acts quickly: by the 2–5-day window after tumor cell death, when antigen-presenting cells accumulate, less than 5% of its activity remains. That timing may make lead-212 particularly well suited to checkpoint combinations. VMT01 is now being studied in a Phase 1/2a melanoma trial, as monotherapy and in combination with nivolumab. New clinical data is expected in late 2026. Read more: tinyurl.com/6kcyud7b #CATX #TargetedAlphaTherapy #Oncology